Immuno-oncology is a rapidly evolving field, and a combination of powerful tools can help identify novel pharmaceutical targets.
The interaction of programmed death-ligand 1 (PD-L1) with PD-1 inhibits T cell activity and proliferation, facilitating immune evasion by cancer cells. Identifying inhibitory signals, such as PD-L1, on the surface of cancer cells has triggered the development of a new class of cancer immunotherapy that interferes explicitly with immune silencing.
This application note demonstrates how you can use knock-out cell lines combined with high-throughput assays to gain a deep understanding of immuno-oncology pathways.
Download now
Abcam will process your personal data in strict accordance with its privacy policy which can be found here. This will include sending you updates about Abcam, our products, and resources we think would be of interest to you. You can unsubscribe and manage your marketing preferences by clicking the link at the bottom of every email we send. By filling out this form you consent to Abcam sharing your details with your local, authorized distributor for the purpose of answering your query.